Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 02 2019
Historique:
received: 27 10 2018
revised: 20 12 2018
accepted: 22 12 2018
pubmed: 3 1 2019
medline: 7 3 2020
entrez: 3 1 2019
Statut: ppublish

Résumé

The optimization campaign for a nitrofuran antitubercular hit (N-benzyl-5-nitrofuran-2-carboxamide; JSF-3449) led to the design, synthesis, and biological profiling of a family of analogs. These compounds exhibited potent in vitro antitubercular activity (MIC = 0.019-0.20 μM) against the Mycobacterium tuberculosis H37Rv strain and low in vitro cytotoxicity (CC

Identifiants

pubmed: 30600207
pii: S0960-894X(18)31001-1
doi: 10.1016/j.bmcl.2018.12.053
pmc: PMC6368976
mid: NIHMS1517707
pii:
doi:

Substances chimiques

Antitubercular Agents 0
Nitrofurans 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

601-606

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI111647
Pays : United States
Organisme : NIAID NIH HHS
ID : R33 AI111647
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI109713
Pays : United States

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Références

Org Lett. 2003 Oct 16;5(21):3799-802
pubmed: 14535713
Bioorg Med Chem Lett. 2018 Oct 1;28(18):3064-3066
pubmed: 30119957
N Engl J Med. 2017 Jan 19;376(3):243-253
pubmed: 28099825
Science. 2008 Nov 28;322(5906):1392-5
pubmed: 19039139
Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):431-6
pubmed: 16387854
J Med Chem. 2005 Dec 29;48(26):8261-9
pubmed: 16366608
J Med Chem. 2004 Oct 7;47(21):5276-83
pubmed: 15456272
PLoS One. 2014 Feb 05;9(2):e87909
pubmed: 24505329
N Engl J Med. 2015 Nov 12;373(20):1986-8
pubmed: 26559594
J Med Chem. 2018 Mar 22;61(6):2166-2210
pubmed: 28850227
Antimicrob Agents Chemother. 2015 Sep;59(9):5316-23
pubmed: 26100695
Antimicrob Agents Chemother. 2013 Aug;57(8):3903-9
pubmed: 23733467
Chem Biol. 2013 Mar 21;20(3):370-8
pubmed: 23521795
Nature. 2000 Jun 22;405(6789):962-6
pubmed: 10879539
PLoS Med. 2006 Nov;3(11):e466
pubmed: 17132069
Nat Chem Biol. 2013 Aug;9(8):499-506
pubmed: 23770708
Antimicrob Agents Chemother. 1994 Sep;38(9):2054-8
pubmed: 7811018
J Antimicrob Chemother. 2008 Nov;62(5):1037-45
pubmed: 18693235
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29311070
ACS Med Chem Lett. 2015 Aug 31;6(10):1041-6
pubmed: 26487909

Auteurs

Ricardo Gallardo-Macias (R)

Department of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Pradeep Kumar (P)

Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Mark Jaskowski (M)

Department of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Todd Richmann (T)

Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Riju Shrestha (R)

Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Riccardo Russo (R)

Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Eric Singleton (E)

Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Matthew D Zimmerman (MD)

Public Health Research Institute, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Hsin Pin Ho (HP)

Public Health Research Institute, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Véronique Dartois (V)

Public Health Research Institute, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Nancy Connell (N)

Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

David Alland (D)

Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA.

Joel S Freundlich (JS)

Department of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, NJ, USA; Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA. Electronic address: freundjs@rutgers.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH